Cybin Inc. Completes Share Consolidation as Part of Growth Strategies
Cybin Inc. (NYSE American: CYBN) is excited to announce that it has successfully finalized a share consolidation initiative designed to enhance its capital structure. This process involves exchanging one new Common Share for every 38 existing shares, marking a key development for the company. The consolidation empowers Cybin to streamline its operations and strengthen its strategic growth.
Effects of the Share Consolidation
The consolidation reduces the total number of issued and outstanding common shares from roughly 759,692,495 to about 19,991,907. This adjustment looks to maintain the relative ownership and voting power of each shareholder within the company. While there may be minor adjustments due to fractional shares, this consolidation strongly indicates Cybin's commitment to improving its market presence.
Additionally, changes will also apply to the exercise prices as well as the number of shares available through the company’s existing warrants and options, ensuring consistency throughout.
About Cybin and Its Goals
Cybin is a recognized leader in the clinical-stage neuropsychiatry field, known for its mission to develop innovative, safe therapeutics tailored specifically for mental healthcare. With a strong focus on addressing significant unmet needs, Cybin is dedicated to transforming the treatment landscape for those dealing with mental health issues.
Leading the Way in Mental Health Innovations
The core of Cybin’s mission is built upon a robust network of world-class partners and esteemed scientists. This celebrated collaboration propels Cybin’s efforts in establishing proprietary drug discovery platforms and developing cutting-edge drug delivery methods. Current projects in progress include CYB003, aimed at treating major depressive disorder, and CYB004, which targets generalized anxiety disorder.
Strategic Positioning and Future Vision
Founded in 2019 and based in Canada, Cybin has grown rapidly, expanding its operations to various regions such as the United States and the United Kingdom. By utilizing these areas, the company aims to broaden its influence and reach within the psychedelic-based therapeutic sector.
With an unwavering focus on thorough research and development, Cybin is optimistic about its growth path. The company's dedication to innovation, along with an expanding pipeline of investigational compounds, positions it advantageously in the shifting healthcare landscape.
Commitment to Safety and Effectiveness
As Cybin continues to forge advancements in therapeutic solutions, it remains steadfast in its commitment to safety and efficacy. The company ensures that all its products undergo comprehensive evaluation and research prior to market introduction. This diligent approach not only adheres to regulatory standards but also underscores Cybin's commitment to enhancing mental healthcare.
Frequently Asked Questions
What is the purpose of the share consolidation completed by Cybin?
The share consolidation aims to optimize Cybin's capital structure, streamline operations, and support growth initiatives.
How many common shares does Cybin have after the consolidation?
Cybin has approximately 19,991,907 common shares outstanding following the consolidation.
What are CYB003 and CYB004?
CYB003 is being developed for major depressive disorder, while CYB004 aims to tackle generalized anxiety disorder.
How does Cybin ensure the safety of its products?
Cybin conducts rigorous scientific research and clinical trials to validate the efficacy and safety of its therapies before market release.
In which regions is Cybin operational?
Cybin operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
